Orthobiologics · London
BMAC (bone marrow aspirate concentrate) London.
Autologous, ultrasound-guided orthobiologic injection for knee and hip osteoarthritis and chronic tendinopathy. Delivered under MHRA and HTA regulation. Evidence is promising but heterogenous and NICE has not approved routine use.
What BMAC is
An autologous, cell-rich injection for joints and tendons.
Your own bone marrow, concentrated in theatre and injected into the painful area under imaging.
BMAC is an autologous orthobiologic injection. A small volume of bone marrow is aspirated from your posterior iliac crest, then concentrated in a closed centrifuge system to yield mesenchymal stromal cells (MSCs), platelets, growth factors and anti-inflammatory cytokines. That concentrate is then delivered under ultrasound or fluoroscopy guidance into the target joint or tendon.
The proposed mechanism is a shift in the joint or tendon environment from catabolic and inflammatory towards anabolic and reparative, mediated by paracrine signalling from the injected cells rather than true tissue regeneration. It is used in orthopaedics as a private, evidence-informed option in patients who have exhausted physiotherapy and simple injections but are not yet candidates for arthroplasty.
Indications
When BMAC is reasonable to consider.
Selected joint and tendon problems where conservative care has plateaued but surgery is not yet the right step.
-
Knee OA (K-L grade 2 to 3)
Moderate radiographic osteoarthritis with persistent pain despite physiotherapy, weight optimisation and simple analgesia.
-
Hip OA (moderate)
Moderate hip osteoarthritis in patients not yet ready for arthroplasty and looking to defer surgery.
-
Achilles tendinopathy
Chronic mid-portion or insertional Achilles tendinopathy that has failed loading programmes.
-
Patellar tendinopathy
Jumper’s knee with persistent symptoms after eccentric loading and shockwave.
-
Gluteal tendinopathy
Greater trochanteric pain from gluteus medius or minimus tendinopathy.
-
Common extensor origin
Recalcitrant lateral epicondylopathy (tennis elbow) not responding to conservative care.
Evidence
Promising but heterogenous, not NICE-approved.
An honest read of the current evidence base for BMAC in musculoskeletal practice.
Small and moderate randomised controlled trials in knee osteoarthritis and chronic tendinopathy suggest that BMAC can reduce pain and improve function over 6 to 12 months in selected patients. However, the evidence base is heterogenous. Study designs, cell counts, injection protocols and outcome measures vary widely, and effect sizes are modest.
NICE has not approved BMAC for routine use in musculoskeletal indications and it remains an experimental, private-pay option in the UK. Head-to-head trials with hyaluronic acid have generally not shown superiority. Any responsible consultant offering BMAC should set realistic expectations, present alternatives and be clear that this is a considered, individualised choice rather than a proven cure.
How the procedure works
Day-case, local anaesthetic, home the same day.
A single planned visit in a CQC registered London theatre.
- 01
Consent and marking
Detailed informed consent covering the experimental status of BMAC. Marking of the posterior iliac crest under aseptic technique.
- 02
Anaesthesia
Local anaesthetic infiltration of skin, subcutaneous tissue and periosteum, with light sedation if preferred.
- 03
Marrow harvest
Around 60 to 120 mL of bone marrow aspirated from the posterior iliac crest using a trocar and multiple redirections.
- 04
Concentration
Centrifugation in a closed disposable kit concentrates mesenchymal stromal cells and platelets to roughly 4 to 8 times baseline.
- 05
Ultrasound-guided injection
The concentrate is injected into the target joint or tendon under ultrasound or fluoroscopy guidance. Day-case discharge.
Efficacy
What the numbers look like.
WOMAC and VAS improvement in the majority of responders at 6 to 12 months, with important caveats.
-
Responders
60 to 70%
Proportion reporting meaningful WOMAC or VAS improvement in select knee OA cohorts at 6 to 12 months.
-
Follow up
limited
Most trials report to 12 months. Longer-term durability and structural change data remain sparse.
-
vs hyaluronic acid
not superior
In most head-to-head randomised trials, BMAC has not clearly outperformed intra-articular hyaluronic acid.
-
Safety
good short term
Autologous product with a low complication rate. Iliac crest soreness for a few days is the commonest issue.
Regulation
MHRA and HTA regulated as an ATMP.
Where the product sits within UK regulation, and why that matters for patient safety.
In the UK, BMAC is treated as an Advanced Therapy Medicinal Product (ATMP) and falls within the remit of the Human Tissue Authority (HTA) and the Medicines and Healthcare products Regulatory Agency (MHRA). Providers must hold the correct HTA licence, use closed processing kits and follow strict traceability and consent standards.
Patients should be cautious of unregulated overseas “stem cell” clinics that market expanded or manipulated cell products outside these frameworks. Reports of serious complications, misleading claims and no meaningful redress when things go wrong are well documented. If you are considering BMAC, confirm MHRA registration and HTA licensing before booking.
Cost in London
£3,500 to £6,500 per injection.
Indicative self-pay pricing. Private medical insurance rarely covers BMAC.
In short
BMAC in London: £3,500 to £6,500 per injection, all inclusive.
The range reflects consultant fee, ultrasound theatre, harvest and processing kit, anaesthetic support and a follow-up review. Repeat injections are priced separately.
Where it is performed
London centres offering BMAC.
A short list of MHRA and HTA regulated London units with an orthobiologics pathway.
-
The Regenerative Clinic (Marylebone)
UK orthobiologics group with published BMAC and Lipogems experience.
-
HCA The Wellington Hospital Orthopaedic
St John’s Wood. Orthopaedic surgeons offering BMAC alongside conventional pathways.
-
Fortius Clinic Orthobiologics
Central London orthopaedic group with a dedicated orthobiologics service.
-
The London Orthopaedic Clinic
Harley Street unit with ultrasound-guided injection theatre.
-
GenesisCare Cromwell Hospital
Selected orthopaedic consultants offering BMAC in a regulated private setting.
-
Guy’s and St Thomas’ Private
Access is generally within research or clinical trial protocols only.
Frequently asked
BMAC, honestly answered.
-
What does the evidence really say about BMAC?
Small-to-moderate randomised trials suggest BMAC can reduce pain and improve function in selected knee osteoarthritis and tendinopathy patients, but results are heterogenous. In most head-to-head trials it has not proved superior to hyaluronic acid. NICE has not approved BMAC for routine use and it remains an experimental, private-pay option. Any consultant offering BMAC should set realistic expectations.
-
Is BMAC covered by private medical insurance?
Almost never. Because BMAC is not NICE-approved and is considered experimental for musculoskeletal indications, Bupa, AXA, Vitality, Aviva, WPA and Cigna typically decline cover. Expect to self-fund.
-
Can BMAC be repeated?
Yes. Some protocols use a single injection, others repeat at 6 to 12 months depending on response. There is no accepted maximum, but each injection requires a fresh marrow harvest and adds cost, so decisions should be response-led.
-
Is BMAC MHRA regulated?
Yes. In the UK, BMAC used for musculoskeletal indications sits within the Human Tissue Authority and MHRA framework for Advanced Therapy Medicinal Products (ATMPs). Reputable clinics operate under HTA licence and MHRA oversight, with fully closed processing kits.
-
Are the "stem cell" claims made online reliable?
Be cautious. BMAC contains mesenchymal stromal cells alongside platelets, growth factors and cytokines, but the numbers of true stem cells are small. Overseas clinics marketing "stem cell cures" or expanded cell products outside regulated frameworks should be treated with scepticism, particularly where NICE and the MHRA have not endorsed the product.
-
Will BMAC delay the need for joint replacement?
It might, in the right patient. In selected people with K-L grade 2 to 3 knee OA who respond well, BMAC can defer surgery by months to a few years. It is not a cure and it does not reverse advanced structural damage. For end-stage disease, arthroplasty remains the definitive option.
Speak to a London orthobiologics consultant
Explore BMAC in London, with a regulated provider.
We match you to a UK GMC registered orthopaedic or sports medicine consultant at an MHRA and HTA regulated London centre. Honest discussion of the evidence, alternatives and realistic expectations included.